Patent · US Active

SiRNA targeting KRAS

US7576197B2 · kind B2 · utility

56Cited by

10References

18Claims

0Family size

Assignee

Dharmacon, Inc. · US

Inventors

Anastasia Khvorova · Boulder, US
Angela Reynolds · Littleton, US
Devin Leake · Denver, US
William Marshall · Boulder, US
Stephen Scaringe · Lafayette, US
Steven Read · Boulder, US

Key dates

Filing date	Dec 9, 2008
Grant date	Aug 18, 2009
Priority date	—
Expiry date	Dec 9, 2028

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/11
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs directed to silencing KRAS, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.